Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 1307 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Endo, Orion to develop cancer drugs

This agreement allows the companies to develop a total of eight ‘discovery phase’ candidates by combining an equal number of programmes. It also permits both the companies to

FDA approves Depomed PHN drug

The once daily tablet, Gralise is developed by Depomed and it is licensed to Abbott Products in US, Mexico and Canada. Depomed CEO Carl Pelzel said the approval

Pharming halts DNage funding

The biotech company during July last year completed the spin-off of DNage as part of which the DNage was to get a bridge funding from the parent company